{"id":1151,"date":"2025-01-07T17:24:33","date_gmt":"2025-01-07T17:24:33","guid":{"rendered":"https:\/\/www.pharmity.com\/?post_type=news&#038;p=1151"},"modified":"2025-01-07T17:29:35","modified_gmt":"2025-01-07T17:29:35","slug":"fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making","status":"publish","type":"news","link":"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/","title":{"rendered":"FDA Issues Draft Guidance on AI Use in Regulatory Decision-Making"},"content":{"rendered":"<p style=\"text-align: left;\">Yesterday 6th January 2025, the U.S. Food and Drug Administration (FDA) released a draft guidance titled <em>&#8220;Considerations for the Use of Artificial Intelligence in Drug and Biological Product Development.&#8221;<\/em> This document provides insights and recommendations on incorporating AI technology into generating safety, efficacy, and quality data to support regulatory decisions.<\/p>\n<p>The guidance emphasizes transparency in the development and application of AI models, particularly regarding their design, validation, and maintenance. It also highlights potential risks and challenges that stakeholders should address when integrating AI into drug development workflows. Early interaction between sponsors and the FDA is strongly encouraged to ensure the responsible and effective use of AI in this context.<\/p>\n<p>This initiative reflects the FDA\u2019s commitment to fostering innovation while ensuring patient safety and regulatory predictability. Industry experts and companies specializing in AI applications for healthcare have welcomed the guidance as a step toward integrating cutting-edge technologies in medical product development.<\/p>\n<p>Stakeholders are invited to review the draft guidance and provide feedback to help shape a regulatory framework that supports robust, ethical, and safe AI applications in the pharmaceutical and biotechnology industries.<\/p>\n<p><a href=\"https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological\">FDA Guidance on AI in Drug Development<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Yesterday 6th January 2025, the U.S. Food and Drug Administration (FDA) released a draft guidance titled &#8220;Considerations for the Use of Artificial Intelligence in Drug and Biological Product Development.&#8221; This document provides insights and recommendations on incorporating AI technology into generating safety, efficacy, and quality data to support regulatory decisions. The guidance emphasizes transparency in [&hellip;]<\/p>\n","protected":false},"featured_media":1088,"template":"","categories":[],"tags":[],"class_list":["post-1151","news","type-news","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FDA Issues Draft Guidance on AI Use in Regulatory Decision-Making - Pharmity<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Issues Draft Guidance on AI Use in Regulatory Decision-Making - Pharmity\" \/>\n<meta property=\"og:description\" content=\"Yesterday 6th January 2025, the U.S. Food and Drug Administration (FDA) released a draft guidance titled &#8220;Considerations for the Use of Artificial Intelligence in Drug and Biological Product Development.&#8221; This document provides insights and recommendations on incorporating AI technology into generating safety, efficacy, and quality data to support regulatory decisions. The guidance emphasizes transparency in [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharmity\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-07T17:29:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pharmity.com\/wp-content\/uploads\/2024\/10\/25-1024x768.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/\",\"url\":\"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/\",\"name\":\"FDA Issues Draft Guidance on AI Use in Regulatory Decision-Making - Pharmity\",\"isPartOf\":{\"@id\":\"https:\/\/www.pharmity.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/www.pharmity.com\/wp-content\/uploads\/2024\/10\/25.png\",\"datePublished\":\"2025-01-07T17:24:33+00:00\",\"dateModified\":\"2025-01-07T17:29:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/#primaryimage\",\"url\":\"http:\/\/www.pharmity.com\/wp-content\/uploads\/2024\/10\/25.png\",\"contentUrl\":\"http:\/\/www.pharmity.com\/wp-content\/uploads\/2024\/10\/25.png\",\"width\":3200,\"height\":2400},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.pharmity.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Issues Draft Guidance on AI Use in Regulatory Decision-Making\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.pharmity.com\/#website\",\"url\":\"https:\/\/www.pharmity.com\/\",\"name\":\"Pharmity\",\"description\":\"Pharmacy + Quality\",\"publisher\":{\"@id\":\"https:\/\/www.pharmity.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.pharmity.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.pharmity.com\/#organization\",\"name\":\"Pharmity\",\"url\":\"https:\/\/www.pharmity.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.pharmity.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/i0.wp.com\/www.pharmity.com\/wp-content\/uploads\/2018\/05\/P-on-top-1.png?fit=548%2C348&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/www.pharmity.com\/wp-content\/uploads\/2018\/05\/P-on-top-1.png?fit=548%2C348&ssl=1\",\"width\":548,\"height\":348,\"caption\":\"Pharmity\"},\"image\":{\"@id\":\"https:\/\/www.pharmity.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/pharmity\/\",\"https:\/\/www.pinterest.es\/pharmity\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Issues Draft Guidance on AI Use in Regulatory Decision-Making - Pharmity","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/","og_locale":"en_US","og_type":"article","og_title":"FDA Issues Draft Guidance on AI Use in Regulatory Decision-Making - Pharmity","og_description":"Yesterday 6th January 2025, the U.S. Food and Drug Administration (FDA) released a draft guidance titled &#8220;Considerations for the Use of Artificial Intelligence in Drug and Biological Product Development.&#8221; This document provides insights and recommendations on incorporating AI technology into generating safety, efficacy, and quality data to support regulatory decisions. The guidance emphasizes transparency in [&hellip;]","og_url":"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/","og_site_name":"Pharmity","article_modified_time":"2025-01-07T17:29:35+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/www.pharmity.com\/wp-content\/uploads\/2024\/10\/25-1024x768.webp","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/","url":"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/","name":"FDA Issues Draft Guidance on AI Use in Regulatory Decision-Making - Pharmity","isPartOf":{"@id":"https:\/\/www.pharmity.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/#primaryimage"},"image":{"@id":"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/#primaryimage"},"thumbnailUrl":"http:\/\/www.pharmity.com\/wp-content\/uploads\/2024\/10\/25.png","datePublished":"2025-01-07T17:24:33+00:00","dateModified":"2025-01-07T17:29:35+00:00","breadcrumb":{"@id":"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/#primaryimage","url":"http:\/\/www.pharmity.com\/wp-content\/uploads\/2024\/10\/25.png","contentUrl":"http:\/\/www.pharmity.com\/wp-content\/uploads\/2024\/10\/25.png","width":3200,"height":2400},{"@type":"BreadcrumbList","@id":"https:\/\/www.pharmity.com\/news\/fda-issues-draft-guidance-on-ai-use-in-regulatory-decision-making\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pharmity.com\/"},{"@type":"ListItem","position":2,"name":"FDA Issues Draft Guidance on AI Use in Regulatory Decision-Making"}]},{"@type":"WebSite","@id":"https:\/\/www.pharmity.com\/#website","url":"https:\/\/www.pharmity.com\/","name":"Pharmity","description":"Pharmacy + Quality","publisher":{"@id":"https:\/\/www.pharmity.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pharmity.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.pharmity.com\/#organization","name":"Pharmity","url":"https:\/\/www.pharmity.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pharmity.com\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/www.pharmity.com\/wp-content\/uploads\/2018\/05\/P-on-top-1.png?fit=548%2C348&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.pharmity.com\/wp-content\/uploads\/2018\/05\/P-on-top-1.png?fit=548%2C348&ssl=1","width":548,"height":348,"caption":"Pharmity"},"image":{"@id":"https:\/\/www.pharmity.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/pharmity\/","https:\/\/www.pinterest.es\/pharmity\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/news\/1151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/types\/news"}],"version-history":[{"count":4,"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/news\/1151\/revisions"}],"predecessor-version":[{"id":1153,"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/news\/1151\/revisions\/1153"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/media\/1088"}],"wp:attachment":[{"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/media?parent=1151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/categories?post=1151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/tags?post=1151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}